by Rod Raynovich | May 6, 2011 | 2024-25 Life Science Portfolios, BIOgraph, Macro
Biotechs Rally Unphased by Macro Concerns The market loved the jobs report after the nasty commodity meltdown yesterday but other news intervened and buyers left for the weekend. The Dow was up as much as 175 pts and is now trying to hold 12637 up 55 pts. The S&P...
by Rod Raynovich | May 4, 2011 | BIOgraph, Macro
An excellent perspective on the Medical Sciences in a panel by leading scientists was presented Monday at the Milken Institute Global Conference, “Shaping the Future” at the Beverly Hilton in Los Angeles May 2-4. Over 3000 people attended the Conference...
by Rod Raynovich | May 4, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Biotechnology Sector Steps Back after Meteoric Rise Since Early March With many life science indices reaching new highs both YTD and in some cases over 10 years traders decided it was time to put away some cash. Don’t fret yet as we are still way above March...
by Rod Raynovich | May 2, 2011 | 2024-25 Life Science Portfolios, BIOgraph
According to data compiled by the Wall Street Journal on Monday May 2 page R8, the Health and Biotechnology sectors led the market (excluding gold oriented funds) in 2011 up 13.2% YTD and 6.7% in April.In the number two position was small cap growth up 13% and mid cap...
by Rod Raynovich | Apr 29, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Earnings season has begun with good results. Keep in mind the following trends: technology convergence, molecular diagnostics and M&A. The backdrop for the tools market is proposed government cuts in government scientific spending especially NIH. Leerink Swann...
by Rod Raynovich | Apr 28, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Earnings season for diagnostics and tools companies begins today with GenProbe (GPRO $79.39) after the market close. But the stock is up 13% today on a Bloomberg scoop that the Company has hired Morgan Stanley as an investment banker to seek a buyer. The market cap is...
by Rod Raynovich | Apr 27, 2011 | 2024-25 Life Science Portfolios, BIOgraph
The biotech bulls are in charge this week. The sellers must have been watching the Bernanke Press Conference today or maybe buying gold as biotech stocks had one of their best days of the year. The bellwether ETF IBB was up 2.37% to $108.71 an all time high exceeding...
by Rod Raynovich | Apr 26, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Vertex (VRTX $54.17) soared 12.75% today on expectations for FDA approval of it telaprevir HCV drug Thursday April 28. Today FDA staff in a preliminary review commented that the Vertex drug when combined with current therapies is more effective than those drugs alone....
by Rod Raynovich | Apr 25, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Caution is still on as we have had big moves YTD and speculative stocks are selling off. High flyers Amarin (AMRN $16.10) is down 4.85% on volume of 6.85M shares while Ariad (ARIA $8.14) was down 3.2% on volume of 1.5M shares.. Vertex(VRTX $48.04) down 2.69%...
by Rod Raynovich | Apr 21, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Biogen(BIIB $103) soared 19% today reporting profit of $294.3M EPS of $1.20 compared to $217.4 and EPS of 0.80 in the previous year. Revenue from its drug Tysabri used to treat Crohn’s and MS grew 15% to $251M. The Company also reported late stage clinical...
